ISSN:2584-2706 DOI: https://doi.org/10.5281/zenodo.21525903

Smoking and Hypertension Mechanisms, Risks, and Clinical Implications a Comprehensive Review

Tuhin Kumar Sadhu
Lecturer in Pharmacy, Siliguri Govt. Polytechnic

Piyush Ghosh; Pijush Karmakar; Anuska Bhowmik
Karishma De Sarkar; Tushar Ghosh
Diploma In Pharmacy (Part-II),Siliguri Govt. Polytechnic,1 No.
Dabgram Colony, Rabindra Sarani, Siliguri, District -Darjeeling,
734006, West Bengal

Abstract
Tobacco smoking is a major modifiable risk factor for cardiovascular disease, affecting blood pressure & arterial health. It reviews how cigarette smoking interacts with hypertension causing immediate hemodynamic changes, chronic vascular damage & increased cardiovascular risk through mechanisms like sympathetic activation,endothelial dysfunction, oxidative stress& atherosclerosis
Smoking combined with hypertension sharply raises the risk of myocardial infarction, stroke & renal failure. The most effective intervention for hypertensive smokers is cessation, which improves vascular recovery.

Keywords: hypertension, tobacco smoking, cardiovascular risk, arterial stiffness, endothelial dysfunction, smoking cessation, antihypertensive therapy

1. Introduction

Hypertension affects over 1.28 billion adults worldwide & is a major preventable cause of cardiovascular mortality. Tobacco smoking (affecting ~1.3 billion people) has a strong link with elevated blood pressure but the mechanism by which smoking drives hypertension aren't fully understood in clinical practice. Smoking causes an acute, rise in blood pressure with each cigarette, while chronic smoking leads to lasting structural & functional arterial changes. The review aims to integrate evidence on hemodynamic physiology, vascular biology, clinical outcomes, drug interactions & smoking-cessation effects to provide a practical framework for clinicians managing hypertensive patients who smoke
This review provides a comprehensive synthesis of the mechanisms by which smoking and tobacco products elevate blood pressure, quantifies associated cardiovascular risks, and evaluates the evidence base for smoking cessation as a hypertension intervention, and highlights clinical and public health implications.

2. Epidemiology and Background

The co-prevalence of smoking and hypertension is clinically significant. Cross-sectional studies consistently show that smokers have higher ambulatory blood pressure values compared with non-smokers, even when clinic measurements appear similar.
Longitudinal data indicates that sustained heavy smoking is an independent predictor of incident hypertension. The dose-response relationship between pack-years of smoking and hypertension risk

ISSN:2584-2706 DOI: https://doi.org/10.5281/zenodo.21525903

has been confirmed in multiple large cohort studies, with heavier smokers demonstrating both higher absolute blood pressures and greater arterial stiffness indices.

The cardiovascular safety of e-cigarettes and heated tobacco products has been subject to intense scrutiny. A comprehensive mechanistic study by Olfert and colleagues demonstrated that chronic e-cigarette vapor (ECV) exposure in mice activates NADPH oxidase, and generates a superoxide-peroxynitrite cycle leading to progressive vascular endothelial dysfunction and systemic hypertension. Crucially, these effects were observed even with nicotine-free aerosols.

A 2025 systematic review of nicotine-free e-cigarettes confirmed that human trials consistently demonstrate acute endothelial dysfunction, increased arterial stiffness, and transient BP elevation following NFEC exposure. The European Society of Cardiology stated in 2024 that 'no form of nicotine use is safe for cardiovascular health.

3. Pathophysiological Mechanisms

The mechanisms by which smoking elevates and sustains blood pressure are multifactorial and interactive. The primary pathways are outlined below.

3.1 Acute Nicotine-Mediated Sympathetic Activation

Nicotine, the primary alkaloid in tobacco, rapidly crosses the blood line barrier and binds to nicotine acetylcholine receptors in the central nervous system and adrenal medulla. It trigger release of catecholamines, principally adrenaline and noradrenaline, producing a cascade of cardiovascular effects: Increase heart rate, enhanced myocardial contractility, systemic vasoconstriction.

Ambulatory blood pressure monitoring studies confirm that active smokers maintain significantly higher 24-hour blood pressure profiles than non-smokers.

Acute BP rises of 5-10 mm Hg of a heavy smoker.

3.2 Endothelial Dysfunction and Reduced Nitric Oxide Bioavailability

The vascular endothelium regulates blood-vessel tone by constitutive production of Nitric Oxide (NO), a strong vasodilator. Tobacco smoke, which contains over 4,000 chemicals, directly injure the endothelium and hampers its synthesis and release of NO. Oxidative stress from smoke's reactive oxygen species destroys NO before it can relax vascular smooth muscle shifting the vessel response toward vasoconstriction, platelet aggregation and endothelial inflammation. This dysfunctions detectable even in young smokers**.**

3.3 Arterial Stiffness and Reduced Compliance

Chronic tobacco exposure accelerates structural changes in arterial walls, reducing their expansion and recoil each cardiac cycle. Also includes increased collagen deposition, fragmentation of elastin fibers, medial smooth muscle hypertrophy. Overtime, this promotes ventricular hypertrophy, a major independent risk factor for heart failure, arrhythmia and sudden cardiac death.

3.4 Accelerated Atherosclerosis

Smoking is a major accelerators of Atherosclerosis. It causes endothelial injury, oxidizes low-density lipoprotein triggers inflammation. Renal artery atherosclerosis is especially relevant to hypertension. Significant renal artery stenosis activates the renin-angiotensin-aldosterone system, producing secondary hypertension that often resists standard drug therapy. Chronic smoking also disrupting auto regulation of glomerular pressure, which results in proteinuria and progressive nephron loss.

3.5 Oxidative Stress and Systemic Inflammation

Beyond endothelial effects, the oxidative burden of tobacco smoke drives systemic inflammation via activation of nuclear factor Kappa B (NF-Kappa B) pathways, up regulation of pro-inflammatory cytokines including interleukin-6 and tumor necrosis factor-alpha and impaired antioxidant defenses. These inflammatory mediators further damage vascular structures, reduce baroreceptor sensitivity.

Baroreceptor dysfunction is particularly relevant: Increased blood pressure variability of mean pressure, is a recognized predictor of stroke and cardiovascular mortality.

4. Compounded Cardiovascular Risk

When smoking and hypertension occur together, the risk is not just additive but multiplicative. Both conditions damage the blood vessel lining, increase platelet aggregation, and speed up atherosclerosis. As a result, their combined effect greatly raises the chance of acute cardiovascular events.

4.1 Myocardial Infarction and Coronary Artery Disease

ISSN:2584-2706 DOI: https://doi.org/10.5281/zenodo.21525903

Smokers with hypertension have about 2-4 times higher risk of heart attack compared to non-smokers with hypertension. Tobacco smoke increases inflammation and oxidative stress on vessel walls. Together they promote plaque rapture, making arteries more prone to clot formation and leading to myocardial infraction.

4.2 Stroke

Hypertension is the most important modifiable risk factor for stroke. Smoking alone can double the risk by damaging arterial, promoting atrial fibrillation, and disturbing blood flow regulation in the brain. When both factors are present, the overall risk increases significantly especially in women and younger individuals.

4.3 Chronic Kidney Disease

The kidneys are highly sensitive to both pressure and toxins. Smoking causes direct kidney damage, including reduced blood flow and arterial changes. When combined with hypertension, it accelerates kidney damage and may lead to end stage renal disease. Proteinuria is often seen earlier and more frequently in such patients.

4.4 Peripheral Arterial Disease

Smoking is the strongest risk factor for peripheral arterial disease. Hypertension further worsens the condition by damaging arterial walls and reducing blood supply. Together, they increase the risk of severe limb ischemia, amputation, and cardiovascular death.

5. Pharmacological Interactions with Antihypertensive Therapy

Smoking does not merely add to hypertensive risk; it actively undermines therapeutic efforts to manage blood pressure. Several drug-specific interactions are clinically important.

5.1 Beta-Blockers

Beta-adrenergic receptor blocker are a cornerstone of antihypertensive and cardio protective therapy, particularly in patients with coronary artery disease or heart failure. Smoking significantly attenuates the efficacy of beta-blockers through several mechanisms. Nicotine induced sympathetic activation opposes beta-blockade, reducing its antihypertensive effect. Additionally, smoking induces hepatic cytochrome P450 enzymes, accelerating the metabolism of certain beta-blockers including propranolol and metoprolol, thereby reducing plasma drug levels and duration of action.

Clinical consequence: smokers on beta-blockers frequently require higher doses to achieve equivalent blood pressure control and may demonstrate attenuated heart rate response, reducing their usefulness as a marker of adequate dosing

5.2 Calcium Channel Blockers and ACE Inhibitors

Dihydropyridine calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors retain relatively greater efficacy in smokers compared with beta-blockers, making them preferable first line choices in this population.

5.3 Polypharmacy and Combination Therapy

Because smoking impairs the efficacy of antihypertensive drugs, many smoking hypertensive require combination therapy to achieve guideline-recommended targets. This increases pill burden, side effect exposure, and healthcare costs. Some patients are erroneously labelled as having resistant hypertension when inadequate drug efficacy in the context of ongoing smoking is the primary barrier of BP control.

6. Smoking Cessation and Vascular Recovery

Cessation of tobacco use initiates a well-characterized timeline of cardiovascular recovery that has been documented across multiple large prospective cohorts.

6.1 Immediate and Short-Term Recovery

Within 20 minutes of the final cigarette, heart rate and blood pressure begin to decline. Carbon monoxide clears from the bloodstream within 12 hours, normalizing hemoglobin oxygen-carrying capacity. Within 2-12 weeks, endothelial function begins to improve as NO bioavailability recovers and vascular inflammation subsides.

6.2 Medium-Term Recovery (Months to 1 Year)

Arterial stiffness, as measured by pulse wave velocity, shows significant improvement at 6-12 months past-cessation, though residual stiffness may persist compared with lifelong non-smokers. The risk of

ISSN:2584-2706 DOI: https://doi.org/10.5281/zenodo.21525903

coronary heart disease drops to approximately half that of a continuing smoker within 1 year. Baroreceptor sensitivity partially recovers, reducing blood pressure variability.

Time since quitting	Key recovery milestone
20 minutes	Heart rate and blood pressure begin to fall
12 hours	Carbon monoxide cleared; oxygen levels normalise
2–12 weeks	Endothelial function and nitric oxide production improve
6–12 months	Arterial stiffness measurably reduced; ambulatory BP improves
1 year	Coronary heart disease risk reduced to ~50% of continuing smoker
5–15 years	Stroke and MI risk approach levels of lifelong non-smokers

6.3 Long-Term Recovery (5-15 Years)

Over 5-15 years of sustained abstinence, the risk of stroke and myocardial infarction approaches but does not fully equal that of a lifelong non-smoker. Some structural vascular changes, including established atherosclerotic plaques and medial arterial fibrosis, may be partially or fully irreversible.

7. Clinical Implications and Management

The clinical management of a hypertensive patient who smokes requires integration of blood pressure control, cardiovascular risk stratification, and cessation support by the several practical points.

- For smokers blood pressure checks by ambulatory than a single reading. That's because people often skip. Smoking before an appointment that can temporarily lower the pressure and give a falsely normal result.
- Calcium channel blockers and ACE inhibitors or angiotensin receptor blockers and beta-blockers are first-line agents for active smoker's treatment. That given efficacy of beta-blockers in this population. The treatment may need to be more aggressive in smokers. The smoker increase the rate of end organ damage relative to non-smokers at same blood pressure levels.
- The smoking should be treated as a component of antihypertensive treatment not as only a lifestyle recommendation.
- Pharmacological treatment (Varenicline, Bupropion, and Nicotine) should be routinely offered. People with high blood pressure should have their kidney function checked in timely. Smoking and hypertension put extra strain on the kidneys.
- A critical clinical challenge is the widespread patient perception that e-cigarettes and HTPs are safe alternatives to combustible cigarettes. Clinicians must communicate clearly that no currently available nicotine delivery system has been shown to be cardiovascular safe. E-cigarettes impair endothelial function, raise arterial stiffness, and elevate blood pressure through both nicotine-dependent and nicotine-independent aerosol toxicity mechanisms. The WHO does not endorse e-cigarettes as cessation tools

Patient should know the quitting smoking can make blood pressure work better & may let them lower the dose over time.

8. Future Research Directions

Several important knowledge gaps remain in the field of smoking and hypertension:

- Long-term cardiovascular outcomes of chronic e-cigarette use remain incompletely characterized, with most current data limited to acute or short-term exposures. Prospective cohort studies with hard CV endpoints are urgently needed.

ISSN:2584-2706 DOI: https://doi.org/10.5281/zenodo.21525903

- Sex-specific differences in smoking-related HTN mechanisms — including the role of sex hormones in modulating oxidative stress and sympathetic tone — warrant dedicated investigation, as current evidence is predominantly derived from male cohorts.
- Epigenetic modifications — DNA methylation and histone acetylation changes induced by tobacco — as mediators of hypertension development and intergenerational cardiovascular risk transmission represent a frontier area with significant translational potential.
- The optimal integration of GLP-1 receptor agonists and other metabolic agents into smoking cessation programs for hypertensive patients, specifically targeting post-cessation weight gain and BP stabilization, merits dedicated RCT investigation.

9. Conclusions

The relationship between smoking and hypertension is clinically and biologically profound. Smoking increases blood pressure acutely through Nicotin-mediated, sympathetic activation and chronically through endothelial dysfunction, arterial stiffening, and accelerated atherosclerosis. When someone already has high blood pressure, smoking multiplies their risk of stroke, heart attack, kidney failure and cardiovascular death.

Quitting is a single most powerful step: - Blood vessels recovered significantly within weeks to years. For hypertensive patients, cessation isn't optional advice but an urgent, are part of blood pressure management.

References

Note: This review is based on established cardiovascular and pharmacological evidence. For clinical use, readers are directed to current national and international hypertension guidelines, including those from the European Society of Cardiology (ESC), American Heart Association (AHA), and the World Health Organization (WHO) tobacco cessation frameworks.

1.World Health Organization. Global report on hypertension: the race against a silent killer. WHO, 2023.

2.Whelton PK, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127-e248.

3. Leone A. Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: risk of cardiovascular disease and preventive measures. Curr Pharm Des. 2003;9(29):2417-2423.

4. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24):2295-2303.

5. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease. J Am Coll Cardiol. 2004;43(10):1731-1737.

6.Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscler Thromb Vasc Biol. 2013;33(7):1460-1467.

7.GBD 2019 Risk Factor Collaborators. Global burden of cardiovascular disease attributable to smoking, 1990–2019: an analysis of the 2019 Global Burden of Disease Study. Lancet. 2020. doi:10.1016/S0140-6736(20)30752-2

8. Chen X et al. Advancements in cardiovascular disease research affected by smoking. Rev Cardiovasc Med. 2024;25(8):298. doi:10.31083/j.rcm2508298

9. Gao N et al. Assessing the association between smoking and hypertension: smoking status, type of tobacco products, and interaction with alcohol consumption. Front Cardiovasc Med. 2023;10:1027988.

10. Primatesta P et al. Association between smoking and blood pressure. Hypertension. 2001;37(2):187–193.

11. Yamato I et al. Impact of smoking status on incident hypertension in a Japanese occupational population. Hypertens Res. 2025;48:180–188.

12. Münzel T et al. Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes. Eur Heart J. 2020;41:4057–4070.

13. Benowitz NL et al. Impact of nicotine-free electronic cigarettes on cardiovascular health: a systematic review. J Clin Med. 2025;14(24):8717.

14. Tousoulis D et al. Nicotine and the cardiovascular system: unmasking a global public health threat. Eur Heart J. 2025. doi:10.1093/eurheartj/ehaf1010

15. Lim SS et al. The association between smoking behavior and the risk of hypertension: review of observational and genetic evidence. J Multidiscip Healthc. 2024;17:3213–3228.

16. Morawietz H et al. Regulation of endothelial function by cigarette smoke and next-generation tobacco and nicotine products. Antioxidants (Basel). 2023;12(2):281.

17. Olfert IM et al. Electronic cigarette exposure causes vascular endothelial dysfunction via NADPH oxidase activation and eNOS uncoupling. Am J Physiol Heart Circ Physiol. 2022;322:H639–H650.

18. Dikalov S, Dikalova A. Tobacco smoking induces cardiovascular mitochondrial oxidative stress, promotes endothelial dysfunction and enhances hypertension. Am J Physiol Heart Circ Physiol. 2019. doi:10.1152/ajpheart.00121.2019

19. Morita H et al. Smoking cessation and vascular endothelial function. Hypertens Res. 2023;46:2765–2775.

20. Boutouyrie P et al. Arterial stiffness and cardiovascular risk in hypertension. Circ Res. 2021;128:864–886.

21. Vlachopoulos C et al. Electronic cigarette smoking increases aortic stiffness and blood pressure in young smokers. J Am Coll Cardiol. 2020. doi:10.1016/j.jacc.2020.01.042

22. Chen X et al. Advancements in cardiovascular disease research affected by smoking. Rev Cardiovasc Med. 2024;25(8):298.

23. Tousoulis D et al. (European Heart Journal 2025, citing ESC 2024 Position). Nicotine and the cardiovascular system.

24. Agbaje AO et al. Tobacco and electronic cigarette use with hypertension and the mediating effect of dyslipidemia – NHANES study. Am J Physiol Heart Circ Physiol. 2025;329:H889–H898.

25. Jiang H et al. Passive smoking and the risk of hypertension in nonsmoking adults: systematic review and meta-analysis. PeerJ. 2026;14:e20639.

26. Vera-Ponce VJ et al. Differential assessment of the global tobacco index and smoking intensity and duration on blood pressure in Peruvian adults. J Clin Med. 2026;15(3):1030.

27. Chien WC et al. Tobacco use disorder is associated with increased risk of cardiomyopathy: population-based study from Taiwan. Sci Rep. 2025. doi:10.1038/s41598-025-30328-3

28. Ambrose JA et al. Cardiovascular effects of smoking and smoking cessation: a 2024 update. Cardiol Rev. 2025.

29. Jones A et al. Nicotine exposure: a catalyst for nitrosative and oxidative stress in glomerular podocytes and renal impairment. Hypertension. 2024;81(suppl 1):P203.

30. Minami J et al. Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. Hypertension. 1999;33:586–590.

31. Gaya PV et al. Smoking cessation decreases arterial blood pressure in hypertensive smokers: GENTSMOKING RCT subgroup analysis. Tob Induc Dis. 2024;22:80.

32. Tsai SY et al. The role of smoking cessation programs in lowering blood pressure: a retrospective cohort study. Tob Induc Dis. 2021;19:82.

33. Beck J et al. Blood pressure changes during smoking cessation in a randomized, double-blind, placebo-controlled trial of dulaglutide treatment. Eur J Prev Cardiol. 2023. doi:10.1093/eurjpc/zwad271

34. Pimenta E et al. Smoking and the risk of resistant hypertension: a systematic review. J Hum Hypertens. 2021.

35. Polosa R et al. Addressing the dual challenge: managing smoking cessation in patients with diabetes. World J Diabetes. 2025;16(12):105241.

36. Li Y et al. Antenatal nicotine exposure results in heightened oxidative stress and vascular hypertensive reactivity via Nox2-dependent mechanism. Br J Pharmacol. 2011. doi:10.1111/j.1476-5381.2011.01393.x

37. Paranthaman S et al. Tobacco smoking in India: critical analysis of its cardiovascular impact and need for comprehensive control measures. J Curr Cardiol. 2025;3(3):100–111.

ISSN:2584-2706 DOI: https://doi.org/10.5281/zenodo.21525903

38. Mancia G et al. 2023 ESH guidelines for the management of arterial hypertension. J Hypertens. 2023. doi:10.1097/HJH.0000000000003480

39. Whelton PK et al. 2017 ACC/AHA guideline for prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71:1269–1324.